Brookline Capital Markets initiated coverage of Medicus Pharma (NASDAQ:MDCX) with a buy rating, citing the potential of its ...

IPO in U.S. Provides Additional Funding & Common Stock that Trades on Nasdaq On November 14, 2024, Medicus Pharma Ltd. (TSXV:MDCX) closed an IPO (Initial Public Offering) in the United States.

Medicus Pharma Ltd (MDCX) has received a new Buy rating, initiated by Brookline Capital Markets analyst, Kumaraguru Raja.Don't Miss Our ...

Medicus Pharma (MDCX) announces that its Investigational New Animal Drug, INAD, has received Minor Use in Major Species Designation, MUMS, from the U.S. Food and Drug Administration, FDA ...

Canadian life sciences company Medicus Pharma has partnered with Japanese healthcare consultancy Swanielle to expand its Phase II clinical trial for treating basal cell carcinoma (BCC) into the ...

Medicus Pharma Ltd. is a clinical stage, multi-strategy holding company, which engages in investing in novel life sciences and bio-technology companies. It focuses on identifying, acquiring ...

This time around, we note that Medicus Pharma hired Faisal Mehmud as chief medical officer. Previously, he worked at GSK, where he was senior vice president, data generation and scientific ...

Brookline analyst Kumaraguru Raja initiated coverage of Medicus Pharma (MDCX) with a Buy rating and $12 price target Medicus is advancing ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Brookline Capital Markets initiated coverage of Medicus Pharma (NASDAQ:MDCX) with a buy rating, citing the potential of its basal cell carcinoma treatment D-MNA. The investment firm noted that D ...